Illumina, an American biotechnology company, headquartered in San Diego, California, completed the spin-off of an 85% stake in GRAIL, an American biotechnology company in Menlo Park, California. "With the completion of the spin-off of GRAIL, we have achieved our goal of divesting GRAIL in a manner that allows its breakthrough technology to continue benefiting patients. Illumina will maintain a minority share of 14.5% in the company. GRAIL plays a critical role in the fight against cancer, and while the company is no longer part of Illumina, we remain confident in its future and will continue to support GRAIL with our sequencing technology, end-to-end workflows, and suite of services," Jacob Thaysen, Illumina CEO.